Commodore Capital LP Takes Position in Alto Neuroscience, Inc. $ANRO

Commodore Capital LP bought a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) in the 4th quarter, Holdings Channel reports. The firm bought 1,823,196 shares of the company’s stock, valued at approximately $32,453,000. Alto Neuroscience makes up approximately 2.2% of Commodore Capital LP’s portfolio, making the stock its 21st largest holding. Commodore Capital LP owned approximately 0.06% of Alto Neuroscience as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Artia Global Partners LP bought a new position in shares of Alto Neuroscience in the 4th quarter valued at about $520,000. Balyasny Asset Management L.P. bought a new stake in shares of Alto Neuroscience in the 4th quarter valued at about $198,000. Boothbay Fund Management LLC lifted its stake in Alto Neuroscience by 329.0% in the 4th quarter. Boothbay Fund Management LLC now owns 139,304 shares of the company’s stock valued at $2,480,000 after purchasing an additional 106,832 shares during the last quarter. 683 Capital Management LLC bought a new position in Alto Neuroscience during the fourth quarter worth about $1,153,000. Finally, ExodusPoint Capital Management LP bought a new position in Alto Neuroscience during the fourth quarter worth about $334,000.

Alto Neuroscience Trading Up 4.2%

ANRO stock opened at $21.87 on Thursday. Alto Neuroscience, Inc. has a 52 week low of $2.15 and a 52 week high of $28.44. The company has a market capitalization of $767.49 million, a PE ratio of -9.04 and a beta of 1.22. The company’s 50-day simple moving average is $22.68 and its 200 day simple moving average is $19.72. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, sell-side analysts anticipate that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

ANRO has been the topic of several research analyst reports. Robert W. Baird dropped their price objective on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a report on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a research report on Monday, March 16th. Finally, JonesTrading decreased their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.25.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.